MUVON Therapeutics AG, a clinical-stage biotechnology company specializing in skeletal muscle regeneration therapies, has announced its participation in the 43rd annual J.P. Morgan Healthcare Conference. The company will highlight the advancement of its lead program targeting Stress Urinary Incontinence (SUI), a condition affecting over 200 million women worldwide.
MUVON recently shared interim data from its ongoing phase 2 SUISSE MPC2 study (NCT05534269), which evaluates the safety and efficacy of its Muscle Precursor Cell (MPC)-based therapy for SUI. The interim results included data from 10 female patients with at least six months of follow-up after receiving injections of the tissue-engineered product into the urethral sphincter muscle.
Based on this interim analysis, the international Data Safety Monitoring Board (DSMB) has recommended the continuation of the study. MUVON remains on track to release final results from the completed phase 2 study in Q3 2025.
This milestone underscores MUVON’s commitment to addressing the unmet needs in SUI treatment through innovative biotechnology solutions.
“We’re delighted to be invited to participate in the J.P. Morgan Annual Healthcare Conference which coincides with an important inflection point as we make steady progress toward addressing the high unmet medical need in patients with stress urinary incontinence,” said Deana Mohr, Chief Executive Officer at MUVON Therapeutics. “We’re looking forward to discussing our future development plans with interested investor audiences and partners as the company is expecting to meet its capitalization objectives in Q1 of this year.”
